Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?

Trastuzumab has recently been introduced as a treatment for HER2-positive metastatic and/or unresectable gastric cancer (MUGC); however, compared with breast cancer, some issues concerning HER2 and trastuzumab therapy for gastric cancer remain unclear. A 74-year-old woman received trastuzumab-contai...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Case Rep Gastrointest Med
Huvudupphovsmän: Ishimine, Yu, Goto, Akira, Watanabe, Yoshito, Yajima, Hidetaka, Nakagaki, Suguru, Yabana, Takashi, Adachi, Takeya, Kondo, Yoshihiro, Kasai, Kiyoshi
Materialtyp: Artigo
Språk:Inglês
Publicerad: Hindawi Publishing Corporation 2015
Ämnen:
Case Report
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4393931/
https://ncbi.nlm.nih.gov/pubmed/25893119
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2015/132030
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk